Remus Pharmaceuticals Limited IPO

Remus Pharmaceuticals Limited IPO Review, Date, Price, GMP, Allotment

Remus Pharmaceuticals Limited, established in 2015, specializes in the commercialization and dissemination of finalized compositions of pharmaceutical medications.

The company’s assortment of products can be categorized into two principal divisions:

  1. Active Pharmaceutical Ingredients (APIs): These are the biologically potent constituents found in drug formulations such as tablets, capsules, creams, and injectables, which generate the desired effects.
  2. Refined Pharmaceutical Formulations: Therapeutic medications are offered in various forms and dosages.

As of January 31, 2023, the company boasts an extensive portfolio comprising 429 different products. These offerings are marketed under diverse brand appellations worldwide. At the date mentioned above, the company had registered 295 products across 13 countries. Furthermore, 134 products were undergoing the registration process in 16 countries.

Moreover, by January 31, 2023, Remus Pharmaceuticals had secured business-to-business supply agreements with 58 domestic distributors and 139 international distributors for the purposes of distribution and/or contract manufacturing supply.

Notably, the company has diligently fostered steadfast and reliable relationships with a diverse clientele spanning over 20 countries. This client base encompasses generic distributors, regional distributors, multinational distributors, as well as hospitals and clinics.

Remus Pharmaceuticals is One of the largest manufacturers and exporters of formulations in India. Remus succeeds in utilizing the best of its resources and manpower to develop its network throughout the world. The company is backed by specialists with 15 years of industry expertise and was built on ties with leading pharmaceutical firms.

Companies Specialties:

  1. Oncology: This specialty focuses on the diagnosis, treatment, and management of various types of cancer.
  2. Probiotics: Probiotics are live microorganisms that provide health benefits when consumed. They are commonly used to promote digestive health and boost the immune system.
  3. Ophthalmic: This specialty relates to the eyes and involves the diagnosis and treatment of eye conditions and diseases.
  4. Contrast Reagents: Contrast reagents, also known as contrast agents or contrast media, are substances used in medical imaging procedures to enhance the visibility of specific organs, tissues, or blood vessels.
  5. Sachets: Sachets are small, sealed packets used for packaging and dispensing various forms of medications or products, such as powders, granules, or liquids.
  6. Inhalers: Inhalers are devices used to deliver medication directly into the lungs for the treatment of respiratory conditions, such as asthma or chronic obstructive pulmonary disease (COPD).
  7. Semi-solids: Semi-solid pharmaceutical preparations refer to formulations that have a partially solid consistency, such as creams, ointments, gels, or pastes.
  8. Large-Volume Parenterals: Large-volume parenteral (LVPs) are sterile solutions or suspensions intended for intravenous administration in large volumes, typically over 100 milliliters. They are commonly used for hydration, nutritional support, or administration of medications.
  9. Injections: Injections involve the delivery of medication or fluids into the body using a needle and syringe. They can be administered intramuscularly, subcutaneously, or intravenously, depending on the specific needs of the patient.
  10. Oral Solids: Oral solids are pharmaceutical formulations in solid dosage forms, such as tablets, capsules, or powders, which are taken orally.
  11. Oral Liquids: Oral liquids refer to liquid pharmaceutical formulations that are meant to be taken by mouth, such as syrups, suspensions, or solutions.

Remus Pharmaceuticals Limited IPO Complete Details:

IPO Date17 May 2023 to 19 May 2023
Issue TypeBook Built Issue
Listing AtNSE SME
Face Value10 Rs. Per Share
PriceRs. 1150 to 1229
Lot Size100
Issue Size388,000 shares (Rs.47.69 Cr)
Fresh Issue388,000 shares (Rs.47.69 Cr)
Listing Date29 May 2023

Remus Pharmaceuticals Limited IPO Timetable:

Opening Date17 May 2023
Closing Date19 May 2023
Allotment24 May 2023
Initiation of Refunds25 May 2023
Credit of Shares to Demat Account26 May 2023
Listing Date29 May 2023
* Date May Change

Company Financial Details:

Period EndedAssetsRevenueProfit After TaxBorrowingsReserves and Surplus
31 March 2020530.361,276.8981.1635.93201.03
31 March 20211,104.961,922.45102.5827.89303.61
31 March 20221,590.932,543.71338.5719.17543.17
30 December 20223,352.963,361.20643.90947.451,603.57
Amount In Lakhs

AS OF NOW, the GMP OF Remus Pharmaceuticals Limited is Around 580 Rs.

Leave a Reply

Your email address will not be published. Required fields are marked *